A summary of nonvested RSU and PSU activity (shares in thousands) is as follows:
## Table 0 ##
At December?31, 2018, there was $560 million of total pretax unrecognized compensation expense related to nonvested stock options, RSU and PSU awards which will be recognized over a weighted average period of 1.9 years.
For segment reporting, share-based compensation costs are unallocated expenses.
Table of Contents 110 14.
???
?Pension and Other Postretirement Benefit Plans The Company has defined benefit pension plans covering eligible employees in the United States and in certain of its international subsidiaries.
In addition, the Company provides medical benefits, principally to its eligible U. S. ?retirees and their dependents, through its other postretirement benefit plans.
The Company uses December?31 as the year-end measurement date for all of its pension plans and other postretirement benefit plans.
Net Periodic Benefit Cost The net periodic benefit cost (credit) for pension and other postretirement benefit plans consisted of the?following components
## Table 1 ##
The changes in net periodic benefit cost (credit) year over year for pension plans are largely attributable to changes in the discount rate affecting net loss amortization.
In connection with restructuring actions (see Note?5), termination charges were recorded in 2018, 2017 and 2016 on pension and other postretirement benefit plans related to expanded eligibility for certain employees exiting Merck.
Also, in connection with these restructuring activities, curtailments were recorded on pension and other postretirement benefit plans and settlements were recorded on certain U. S.  and international pension plans as reflected in the table above.
The components of net periodic benefit cost (credit) other than the service cost component are included in Other (income) expense, net (see Note 15), with the exception of certain amounts for termination benefits, curtailments and settlements, which are recorded in Restructuring costs if the event giving rise to the termination benefits, curtailment or settlement is related to restructuring actions as noted above.
Table of Contents and development expenses.
Reimbursements received from AstraZeneca for research and development expenses are recognized as reductions to Research and development costs.
As part of the agreement, Merck made an upfront payment to AstraZeneca of $1.6 billion and will make payments of up to $750 million over a multi-year period for certain license options (of which $250 million was paid in December 2017, $400 million was paid in December 2018 and $100 million is expected be paid in 2019).
The Company recorded an aggregate charge of $2.35 billion in Research and development expenses in 2017 related to the upfront payment and future license option payments.
In addition, the agreement provides for additional contingent payments from Merck to AstraZeneca related to the successful achievement of regulatory and sales-based milestones.
In 2018, Merck determined it was probable that annual sales of Lynparza in the future would trigger three sales-based milestone payments from Merck to AstraZeneca aggregating $600 million.
Accordingly, in 2018, Merck recorded $600 million of liabilities and a corresponding increase to the intangible asset related to Lynparza, and recognized $58 million of cumulative amortization expense within Cost of sales.
During 2018, one of the sales-based milestones was triggered, resulting in a $150 million payment to AstraZeneca.
In 2018, Merck made an additional?$100 million?sales-based milestone payment, which was accrued for in 2017 when the Company deemed to the payment to be probable.
The remaining $3.4 billion of potential future sales-based milestone payments have not yet been accrued as they are not deemed by the Company to be probable at this time.
In 2018, Lynparza received approval in the United States for the treatment of certain patients with metastatic breast cancer and for use in the first-line maintenance setting for advanced ovarian cancer, triggering capitalized milestone payments of $140 million in the aggregate from Merck to AstraZeneca.
Potential future regulatory milestone payments of $1.76 billion remain under the agreement.
The asset balance related to Lynparza (which includes capitalized sales-based and regulatory milestone payments) was $743 million at December?31, 2018 and is included in Other Assets on the Consolidated Balance Sheet.
The amount is being amortized over its estimated useful life through 2028 as supported by projected future cash flows, subject to impairment testing.
Summarized information related to this collaboration is as follows:
## Table 2 ##
(1) Represents amortization of capitalized milestone payments.
(2) Amount for 2017 includes $2.35 billion related to the upfront payment and future license option payments.
(3) Includes accrued milestone and license option payments.
Eisai In March 2018, Merck and Eisai announced a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima, an orally available tyrosine kinase inhibitor discovered by Eisai.
Under the agreement, Merck and Eisai will develop and commercialize Lenvima jointly, both as monotherapy and in combination with Merck’s anti-PD-1 therapy, Keytruda.
Eisai records Lenvima product sales globally (Eisai is the principal on Lenvima sales transactions), and Merck and Eisai share gross profits equally.
Merck records its share of Lenvima product sales, net of cost of sales and commercialization costs, as alliance revenue.
Expenses incurred during codevelopment, including for studies evaluating Lenvima as monotherapy, are shared equally by the two companies and reflected in Research and development expenses.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS In 2012, we determined the implied fair value of goodwill for the Pullmantur reporting unit was $145.5 million and recognized an impairment charge of $319.2 million based on a probability-weighted discounted cash flow model further discussed below.
This impairment charge was recognized in earnings during the fourth quarter of 2012 and is reported within Impairment of Pullmantur related assets within our consolidated statements of comprehensive income (loss).
During the fourth quarter of 2014, we performed a qualitative assessment of whether it was more-likelythan-not that our Royal Caribbean International reporting unit’s fair value was less than its carrying amount before applying the two-step goodwill impairment test.
The qualitative analysis included assessing the impact of certain factors such as general economic conditions, limitations on accessing capital, changes in forecasted operating results, changes in fuel prices and fluctuations in foreign exchange rates.
Based on our qualitative assessment, we concluded that it was more-likely-than-not that the estimated fair value of the Royal Caribbean International reporting unit exceeded its carrying value and thus, we did not proceed to the two-step goodwill impairment test.
No indicators of impairment exist primarily because the reporting unit’s fair value has consistently exceeded its carrying value by a significant margin, its financial performance has been solid in the face of mixed economic environments and forecasts of operating results generated by the reporting unit appear sufficient to support its carrying value.
We also performed our annual impairment review of goodwill for Pullmantur’s reporting unit during the fourth quarter of 2014.
We did not perform a qualitative assessment but instead proceeded directly to the two-step goodwill impairment test.
We estimated the fair value of the Pullmantur reporting unit using a probability-weighted discounted cash flow model.
The principal assumptions used in the discounted cash flow model are projected operating results, weightedaverage cost of capital, and terminal value.
Significantly impacting these assumptions are the transfer of vessels from our other cruise brands to Pullmantur.
The discounted cash flow model used our 2015 projected operating results as a base.
To that base, we added future years’ cash flows assuming multiple revenue and expense scenarios that reflect the impact of different global economic environments beyond 2015 on Pullmantur’s reporting unit.
We assigned a probability to each revenue and expense scenario.
We discounted the projected cash flows using rates specific to Pullmantur’s reporting unit based on its weighted-average cost of capital.
Based on the probability-weighted discounted cash flows, we determined the fair value of the Pullmantur reporting unit exceeded its carrying value by approximately 52% resulting in no impairment to Pullmantur’s goodwill.
Pullmantur is a brand targeted primarily at the Spanish, Portuguese and Latin American markets, with an increasing focus on Latin America.
The persistent economic instability in these markets has created significant uncertainties in forecasting operating results and future cash flows used in our impairment analyses.
We continue to monitor economic events in these markets for their potential impact on Pullmantur’s business and valuation.
Further, the estimation of fair value utilizing discounted expected future cash flows includes numerous uncertainties which require our significant judgment when making assumptions of expected revenues, operating costs, marketing, selling and administrative expenses, interest rates, ship additions and retirements as well as assumptions regarding the cruise vacation industry’s competitive environment and general economic and business conditions, among other factors.
If there are changes to the projected future cash flows used in the impairment analyses, especially in Net Yields or if certain transfers of vessels from our other cruise brands to the Pullmantur fleet do not take place, it is possible that an impairment charge of Pullmantur’s reporting unit’s goodwill may be required.
Of these factors, the planned transfers of vessels to the Pullmantur fleet is most significant to the projected future cash flows.
If the transfers do not occur, we will likely fail step one of the impairment test.
NOTE 4.
INTANGIBLE ASSETS Intangible assets are reported in Other assets in our consolidated balance sheets and consist of the following (in thousands):
## Table 3 ##
During the fourth quarter of 2014, 2013 and 2012, we performed the annual impairment review of Pullmantur’s trademarks and trade names using a discounted cash flow model and the relief-from-royalty method to compare the fair value of these indefinite-lived intangible assets to its carrying value.
The royalty rate used is based on comparable royalty agreements in the tourism and hospitality industry.
We used a discount rate comparable to the rate used in valuing the Pullmantur reporting unit in our goodwill impairment test.
Based on the results of our testing, we did not

<table><tr><td></td><td colspan="2">RSUs</td><td colspan="2">PSUs</td></tr><tr><td></td><td>Numberof Shares</td><td>WeightedAverageGrant DateFair Value</td><td>Numberof Shares</td><td>WeightedAverageGrant DateFair Value</td></tr><tr><td>Nonvested January 1, 2018</td><td>13,609</td><td>$59.32</td><td>1,868</td><td>$60.03</td></tr><tr><td>Granted</td><td>7,270</td><td>58.46</td><td>1,081</td><td>57.17</td></tr><tr><td>Vested</td><td>-3,766</td><td>59.66</td><td>-758</td><td>57.59</td></tr><tr><td>Forfeited</td><td>-985</td><td>59.30</td><td>-152</td><td>60.06</td></tr><tr><td>Nonvested December 31, 2018</td><td>16,128</td><td>$58.85</td><td>2,039</td><td>$59.42</td></tr></table>
<table><tr><td></td><td colspan="6">Pension Benefits</td><td></td><td></td><td></td></tr><tr><td></td><td colspan="3">U.S.</td><td colspan="3">International</td><td colspan="3">Other Postretirement Benefits</td></tr><tr><td>Years Ended December 31</td><td>2018</td><td>2017</td><td>2016</td><td>2018</td><td>2017</td><td>2016</td><td>2018</td><td>2017</td><td>2016</td></tr><tr><td>Service cost</td><td>$326</td><td>$312</td><td>$282</td><td>$238</td><td>$252</td><td>$238</td><td>$57</td><td>$57</td><td>$54</td></tr><tr><td>Interest cost</td><td>432</td><td>454</td><td>456</td><td>178</td><td>172</td><td>204</td><td>69</td><td>81</td><td>82</td></tr><tr><td>Expected return on plan assets</td><td>-851</td><td>-862</td><td>-831</td><td>-431</td><td>-393</td><td>-382</td><td>-83</td><td>-78</td><td>-107</td></tr><tr><td>Amortization of unrecognized prior service cost</td><td>-50</td><td>-53</td><td>-55</td><td>-13</td><td>-11</td><td>-11</td><td>-84</td><td>-98</td><td>-106</td></tr><tr><td>Net loss amortization</td><td>232</td><td>180</td><td>119</td><td>84</td><td>98</td><td>87</td><td>1</td><td>1</td><td>3</td></tr><tr><td>Termination benefits</td><td>19</td><td>44</td><td>23</td><td>2</td><td>4</td><td>4</td><td>3</td><td>8</td><td>4</td></tr><tr><td>Curtailments</td><td>10</td><td>3</td><td>5</td><td>1</td><td>-4</td><td>-1</td><td>-8</td><td>-31</td><td>-18</td></tr><tr><td>Settlements</td><td>5</td><td>—</td><td>—</td><td>13</td><td>5</td><td>6</td><td>—</td><td>—</td><td>—</td></tr><tr><td>Net periodic benefit cost (credit)</td><td>$123</td><td>$78</td><td>$-1</td><td>$72</td><td>$123</td><td>$145</td><td>$-45</td><td>$-60</td><td>$-88</td></tr></table>
<table><tr><td>Years Ended December 31</td><td>2018</td><td>2017</td></tr><tr><td>Alliance revenue</td><td>$187</td><td>$20</td></tr><tr><td>Cost of sales<sup>-1</sup></td><td>93</td><td>4</td></tr><tr><td>Selling, general and administrative</td><td>48</td><td>1</td></tr><tr><td>Research and development<sup>-2</sup></td><td>152</td><td>2,419</td></tr><tr><td>December 31</td><td>2018</td><td>2017</td></tr><tr><td>Receivables from AstraZeneca included inOther current assets</td><td>$52</td><td>$12</td></tr><tr><td>Payables to AstraZeneca included inAccrued and other current liabilities<sup>-3</sup></td><td>405</td><td>543</td></tr><tr><td>Payables to AstraZeneca includedOther Noncurrent Liabilities<sup>-3</sup></td><td>250</td><td>100</td></tr></table>
<table><tr><td></td><td>2014</td><td>2013</td></tr><tr><td>Indefinite-life intangible asset—Pullmantur trademarks and trade names</td><td>$214,112</td><td>$204,866</td></tr><tr><td>Foreign currency translation adjustment</td><td>-26,074</td><td>9,246</td></tr><tr><td>Total</td><td>$188,038</td><td>$214,112</td></tr></table>

Question: What was the total amount of the Net loss amortization in the years where Settlements greater than 0?
Answer: 805.0